| Identification | Back Directory | [Name]
brusatol | [CAS]
14907-98-3 | [Synonyms]
100935
Brusato1
Yatansin
Brustaol
NSC 172924
(+)-Brusatol
Brusatol >=95% (HPLC)
Picras-3-en-21-oic acid, 13,20-epoxy-3,11,12-trihydroxy-15-[(3-methyl-1-oxo-2-buten-1-yl)oxy]-
13,20-Epoxy-3,11β,12α-trihydroxy-15β-[(3-methyl-1-oxo-2-butenyl)oxy]-2,16-dioxopicras-3-en-21-oic acid methyl ester
13,20-Epoxy-3,11β,12α-trihydroxy-15β-[(3-methyl-1-oxo-2-butenyl)oxy]-2,16-dioxopicrasa-3-ene-21-oic acid methyl ester
Picras-3-en-21-oicacid,13,20-epoxy-3,11,12-trihydroxy-15-[(3-Methyl-1-oxo-2-buten-1-yl)oxy]-2,16-dioxo-,Methyl ester, (11b,12a,15b)-
Picras-3-en-21-oic acid, 13,20-epoxy-3,11,12-trihydroxy-15-[(3-methyl-1-oxo-2-buten-1-yl)oxy]-2,16-dioxo-, methyl ester, (11β,12α,15β)-
methyl (1R,2S,3S,3aS,3a1R,4R,6aR,7aR,11aS,11bR)-1,2,9-trihydroxy-8,11a-dimethyl-4-((3-methylbut-2-enoyl)oxy)-5,10-dioxo-1,4,5,6a,7,7a,10,11,11a,11b-decahydro-2H-3,3a1-(epoxymethano)dibenzo[de,g]chromene-3(3aH)-carboxylate | [Molecular Formula]
C26H32O11 | [MDL Number]
MFCD01746220 | [MOL File]
14907-98-3.mol | [Molecular Weight]
520.53 |
| Chemical Properties | Back Directory | [Boiling point ]
724.3±60.0 °C(Predicted) | [density ]
1.46±0.1 g/cm3 (20 ºC 760 Torr) | [storage temp. ]
-20°C | [solubility ]
DMF: 1 mg/ml; DMSO: 1 mg/ml; DMSO:PBS (pH 7.2) (1:1): 0.5 mg/ml | [form ]
powder | [pka]
8.81±0.70(Predicted) | [color ]
white to beige | [biological source]
(Brucia javanica) | [optical activity]
[α]/D +35 to +44°, c = 0.5 in acetone | [LogP]
0.393 (est) |
| Hazard Information | Back Directory | [Uses]
Brusatol has been used to study the protective role of Nrf2 (nuclear factor, erythroid 2 like 2 ) in intestinal ischemia/reperfusion induced injury. | [Definition]
ChEBI: Brusatol is a triterpenoid. | [Biochem/physiol Actions]
Brusatol promotes Nrf2 (nuclear factor, erythroid 2 like 2 ) ubiquitination and degradation. Brusatol upregulates the expression of multiple ribosomal components and controls macromolecular complex function. | [in vivo]
Brusatol is able to reach the tumor tissue and inhibit the Nrf2 pathway. Nude mice are injected with A549 cells to induce tumor growth, followed by a single i.p. injection of 2 mg/kg Brusatol. Nrf2 protein levels are significantly decreased at 24 h or 48 h postinjection[1].
Cisplatin (2 mg/kg) or Brusatol (2 mg/kg) alone does not inhibit tumor growth significantly, whereas in the combination group, tumor size is significantly reduced[1]. " | Animal Model: | Athymic nude mice 4-6 wk old bearing A549 xenografts[1] | | Dosage: | 2 mg/kg | | Administration: | Treated i.p.; Cisplatin (2 mg/kg), Brusatol (2 mg/kg), or in combination every other day for a total of five times | | Result: | Nrf2 protein levels were significantly decreased at 24 h or 48 h postinjection.
Cisplatin or Brusatol alone did not inhibit tumor growth significantly, whereas in the combination group, tumor size was significantly reduced.?"
|
| [storage]
4°C, protect from light, stored under nitrogen |
|
|